期刊
JOURNAL OF NEUROLOGY
卷 257, 期 9, 页码 1421-1431出版社
SPRINGER HEIDELBERG
DOI: 10.1007/s00415-010-5591-7
关键词
Tumor necrosis factor alpha (TNF-alpha); Anti-TNF-alpha; Neurological adverse events; Demyelinating disease; Infliximab; Etanercept; Adalimumab
Anti-tumor necrosis factor alpha (TNF-alpha) drugs have been successfully used for the treatment of rheumatic autoimmune diseases including rheumatoid arthritis (RA), psoriatic arthritis, psoriasis, ankylosing spondylitis (AS), juvenile chronic arthritis, and Crohn's disease. However, they have been associated with different neurological disorders, including alterations of peripheral nerves, multiple sclerosis (MS), optic neuritis (ON) and acute transverse myelitis (ATM). This article reviews the most current aspect regarding neurological adverse events associated with anti-TNF-alpha drugs with emphasis on the possible explanations for this relation and the pathogenic mechanism of TNF-alpha in neurological disorders.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据